A. V. Safronenko, O. M. Kudelina, E. V. Gantsgorn, M. Kh.-B. Buraeva, M. Kh.-B. Buraeva, A. A. Miteneva, L. R. Shvelidze, D. A. Kalmykova, A. A. Ilyina, V. Z. Lachinov
{"title":"Modern Views and Analysis of Promising Approaches to the Treatment of Melanoma","authors":"A. V. Safronenko, O. M. Kudelina, E. V. Gantsgorn, M. Kh.-B. Buraeva, M. Kh.-B. Buraeva, A. A. Miteneva, L. R. Shvelidze, D. A. Kalmykova, A. A. Ilyina, V. Z. Lachinov","doi":"10.33647/2074-5982-19-3-47-52","DOIUrl":null,"url":null,"abstract":"Melanoma is a malignant tumor that can rapidly develop resistance to treatment because of its high mutational activity. The introduction of tyrosine kinase receptor inhibitors (BRAF, MEK) and cytotoxic T lymphocyte antigen/receptor inhibitors (CTLA4, PD-1) into clinical practice has led to an increase in patient survival rates. In in vitro studies, combining PIK3 and MEK inhibitors demonstrate a pronounced reduction in tumor cell growth. The phenomenon of synthetic lethality is also promising, allowing the high mutational load of melanoma to be used as a tool for the development of more effective drugs.","PeriodicalId":40514,"journal":{"name":"Avances en Biomedicina","volume":"36 1","pages":"0"},"PeriodicalIF":0.1000,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avances en Biomedicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33647/2074-5982-19-3-47-52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Melanoma is a malignant tumor that can rapidly develop resistance to treatment because of its high mutational activity. The introduction of tyrosine kinase receptor inhibitors (BRAF, MEK) and cytotoxic T lymphocyte antigen/receptor inhibitors (CTLA4, PD-1) into clinical practice has led to an increase in patient survival rates. In in vitro studies, combining PIK3 and MEK inhibitors demonstrate a pronounced reduction in tumor cell growth. The phenomenon of synthetic lethality is also promising, allowing the high mutational load of melanoma to be used as a tool for the development of more effective drugs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
